Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with Massdevice +7.
Shares of Mela Sciences (NSDQ:MELA) are on up more than 90 percent in pre-market trading on news that the FDA issued an "approvable letter" for MelaFind, it’s hand-held skin cancer detection device.
Shares of Edwards Lifesciences (NYSE:EW) lost nearly 7 percent today, after a Centers for Medicare & Medicaid decision to review its coverage policy for a type of replacement heart valve.
The once-hot leveraged buyout market for medical device companies is slowing as the souring economy spooks investors, according to a panel of private equity fund managers at the AdvaMed conference in Washington.
Med-tech colossus Boston Scientific (NYSE:BSX) will pay $9.25 million to settle U.S. Justice Dept. allegations that it overcharged federal health programs.
A federal judge in Minnesota orders med-tech goliath Medtronic (NYSE:MDT) to produce documents detailing the safety profile of its controversial Infuse bone growth protein in a shareholders’ lawsuit against the world’s largest pure-play device maker.
The medical device industry, gathered in Washington this week for its annual conference, locks in on the jobs issue in arguing against the impending medical device excise tax. But will it work?
Former Medtronic CEO Bill Hawkins, in an exclusive interview with MassDevice.com, tells us about the one that got away: Guidant Corp.’s stent-making operation.